News

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Getting to the root of patients’ issues can provide support for their cancer journey through accessible means, says Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP.

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.

CAR T-cell therapy is starting to enter treatment conversations sooner with patients with multiple myeloma, according to Nick Barkemeyer, PA-C, MMS.

The BCI and patient goals help oncology nurses counsel patients on endocrine therapy use after 5 years, per Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

According to Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, the availability of 3 CDK4/6 inhibitors in first-line mBC therapy gives patients more choices.

Oncology nurses can help patients and families understand the expectations of pediatric brain cancer survival, says Kasey Rangan, MSN, CPNP-PC, CPHON.

In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary investigators.

Clinical trials can provide patients with myeloproliferative neoplasms expanded treatment options.

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical work with patients involved in trials.

The intersection of cardiology and oncology is greater than nurses and providers may assume, explained 2 experts.

Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP, discusses the role of oncology nurses in genomic testing.

Nurse practitioners should listen to patients’ concerns and be ready with questions when it comes to germline testing, according to an expert.

Oncology nurses and APPs can enhance patients’ comfort by counseling patients on what integrative care is and working to make those options accessible.

Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.

Practicing at top of licensure can create opportunities for oncology APPs to engage with patients and other providers in new ways.

Working with patients in new contexts can provide meaning for oncology PAs, potentially reducing burnout, according to Eric Tetzlaff, MHS, PA-C, DFAAPA.

Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.